GLENMARK

Glenmark’s US Play 💉

Glenmark Pharmaceuticals

is gearing up to strengthen its US generics portfolio! Its US arm, Glenmark Pharmaceuticals Inc., USA, is set to launch Sodium Phosphates Injection USP (15 mM/5 mL, 45 mM/15 mL & 150 mM/50 mL single-dose vials) starting April 2026. 🔹 Bioequivalent & therapeutically equivalent to the reference drug of Hospira, Inc. (NDA 018892) 🔹 US market size: ~$66.8 million (IQVIA, 12M ending Dec 2025) 🔹 Expands Glenmark’s injectable portfolio in the US This launch adds another steady revenue stream in a niche hospital-use injectable segment, a positive move in the competitive US generics space.